Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression, bipolar disorder, and addiction, finding emerging evidence for metabolic and possibly direct neuropsychiatric benefits.
Key findingScoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression,
What the researchers found
Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression, bipolar disorder, and addiction, finding emerging evidence for metabolic and possibly direct neuropsychiatric benefits.
Why it matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The numbers in context
Review covered studies on GLP-1 drugs across depression, schizophrenia, substance use disorders, and other psychiatric conditions.
How the study worked
Study methodology detailed in the full publication.
Who was studied
People with various psychiatric conditions across reviewed studies
What this study cannot tell us
Study limitations in the full publication.
How to read the evidence
Evidence level based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
Questions still open
- What are the long-term implications?
- How do results compare to other evidence?
- What further research is needed?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.
The primary care companion for CNS disorders, 27(3)
Citation
Ali, Mohsan; Ahmed, Ayesha; Khan, Basim Ahmed; Shah, Syeda Taleha; Naveed, Sadiq; Ashraf, Nauman. (2025). Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.. The primary care companion for CNS disorders, 27(3). https://doi.org/10.4088/PCC.24nr03828